Full Story →
$name
Full Story →
$name
Full Story →
Drug-delivery strategy created for central vision loss caused by blood vessel growth at back of eye
Johns Hopkins biomedical engineers have teamed up with clinicians to create a new drug-delivery strategy for a type of central vision loss caused by blood vessel growth at the back of the eye, where such growth should not occur.
Topical formulation identified for prolonged graft survival in corneal transplants
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of therapies that modulate the immune system to treat cancer, infectious diseases, transplant rejection, autoimmune and inflammatory diseases, has ann…
Health Canada approves JETREA® for the treatment of symptomatic vitreomacular adhesion
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, has announced that Health Canada has approved JETREA(R) (ocriplasmin) for the treatment of sym…